of Murine B16 Melanoma Cytokine Products on the Pulmonary Metastasis A Pathogenic Role of Th2 Cells and Their

The role of Th2 cells and the cytokines produced by these cells on experimental pulmonary metastasis of B16 melanoma was investigated in a murine model implanted with high metastatic (B16F10) or low metastatic (B16F1) melanoma cells. An average of 250 colonies of metastasis in the lungs was counted in mice (BF10 mice) at 14 days after the inoculation of 2 3 10 5 B16F10 cells/mouse, while < 20 colonies were detected in mice (BF1 mice) inoculated with the same number of B16F1 cells. CD4 1 CD11b 1 TCR- ab 1 T cells (BF10-Th2 cells) were produced in the spleens of BF10 mice, while these cells were not detected in BF1 mice. The BF10-Th2 cells produced IL-4 and IL-10 into culture fluids when stimulated in vitro with anti-CD3 mAb. However, IL-2 and IFN- g were not produced. The level of a pulmonary metastasis in BF1 mice increased to the level observed in BF10 mice, when BF10-Th2 cells were adoptively transferred to BF1 mice. Also, an increase in the number of pulmonary melanoma was demonstrated in BF1 mice treated with 10 m g/kg murine rIL-4. The level of pulmonary metastasis in BF10 mice or in BF1 mice inoculated with BF10-Th2 cells decreased to the level observed in BF1 mice when mice were treated with an anti-IL-4 mAb at a dose of 250 m g/kg on days 1, 3, and 5 after tumor inoculation. These results suggest that the severity of pulmonary metastasis in mice receiving B16 melanoma cells is strongly influenced by the IL-4 released from tumor-associated Th2 cells.

[1]  X. Cheng,et al.  Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. , 1997, Journal of immunology.

[2]  A. Dalgleish,et al.  Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine. , 1996, Gene therapy.

[3]  D. Herndon,et al.  Interleukin‐12 protects thermally injured mice from herpes simplex virus type 1 infection , 1996, Journal of leukocyte biology.

[4]  A. Sochanik,et al.  Introduction of murine Il-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. , 1995, Cancer letters.

[5]  D. Longo,et al.  Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. , 1995, Journal of the National Cancer Institute.

[6]  Makiko Kobayashi,et al.  CD4+ contrasuppressor T cells improve the resistance of thermally injured mice infected with HSV , 1995, Journal of leukocyte biology.

[7]  G. Dranoff,et al.  Gene therapy of metastatic cancer by in vivo retroviral gene targeting , 1995, Nature Genetics.

[8]  A. McAdam,et al.  Synergistic effects of co‐expression of the Th1 cytokines il‐2 and IFNγ on generation of murine tumor‐reactive cytotoxic cells , 1995, International journal of cancer.

[9]  A. Kehlen,et al.  Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell‐derived cytokines, such as IL‐4 and IL‐13 , 1995, Clinical and experimental immunology.

[10]  I. Schmidt-Wolf,et al.  Cytokines and clinical gene therapy , 1995, European journal of immunology.

[11]  T. Tamiya,et al.  Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. , 1995, Human gene therapy.

[12]  T. Eberlein,et al.  Immunoregulatory effects of CD4+ T helper subsets in human melanoma. , 1995, Surgery.

[13]  J. Krauss,et al.  Enhancement of Immune Reactivity in the Lymph Nodes Draining a Murine Melanoma Engineered to Elaborate Interleukin‐4 , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[14]  R. Fisher,et al.  Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[15]  A. Sher,et al.  Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Thiel,et al.  Interleukin-4 inhibits growth of a human lung-tumor cell-line in-vitro and has therapeutic activity against xenografts of this cell-line in-vivo. , 1993, International journal of oncology.

[17]  R. Martuza,et al.  Treatment of glioma by engineered interleukin 4-secreting cells. , 1993, Cancer research.

[18]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[19]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[20]  R. Moy,et al.  Local expression of antiinflammatory cytokines in cancer. , 1993, The Journal of clinical investigation.

[21]  K. Ando,et al.  Differential induction of prostaglandin E2‐dependent and ‐independent immune suppressor cells by tumor‐derived GM‐CSF and M‐CSF , 1993, Journal of leukocyte biology.

[22]  C. Lindqvist,et al.  Decreased interleukin-2 beta-chain receptor expression by interleukin-4 on LGL: influence on the IL-2 induced cytotoxicity and proliferation. , 1992, Cancer letters.

[23]  G. Gallagher,et al.  Peritumoural IL-4 treatment induces systemic inhibition of tumour growth in experimental melanoma. , 1992, Anticancer research.

[24]  A. Bitonti,et al.  Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C. , 1992, Cancer research.

[25]  F. Luscinskas,et al.  IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. , 1992, Journal of immunology.

[26]  S. Sone,et al.  Down-regulation by interleukin 4 of activation of human alveolar macrophages to the tumoricidal state. , 1991, Cancer research.

[27]  M. Kasahara,et al.  The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. , 1991, Journal of immunology.

[28]  S. Mizel,et al.  Partial purification of an immunosuppressive protein from a human tumor cell line and analysis of its relationship to transforming growth factor beta. , 1989, Cellular immunology.

[29]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[30]  M. Awwad,et al.  The immune response to tumors. , 1989, Transplantation proceedings.

[31]  I. Nabi,et al.  Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant. , 1988, Cancer research.

[32]  Z. L. Herd Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies. , 1987, Cancer research.

[33]  R. Pollard,et al.  Importance of Lyt 1+ T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type Tubercle bacilli. , 1986, Journal of the National Cancer Institute.

[34]  B. Mukherji,et al.  Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. , 1986, Journal of immunology.

[35]  V. Ling,et al.  Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. , 1984, Science.

[36]  J. Werkmeister,et al.  Suppressor cell activity in melanoma patients. I. Relation to tumor growth and immunoglobulin levels in vivo , 1981, International journal of cancer.

[37]  I. Fidler,et al.  The pathogenesis of cancer metastasis , 1980, Nature.

[38]  J. Vaage Circulating tumor antigens versus immune serum factors in depressed concomitant immunity. , 1974, Cancer research.

[39]  C. Casciani,et al.  Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression , 1996, Cancer Immunology, Immunotherapy.

[40]  西岡 安彦 Down-regulation by interleukin 4 of activation of human alveolar macrophages to the tumoricidal state , 1993 .

[41]  G. Haas,et al.  Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. , 1993, The Journal of clinical investigation.

[42]  O. Yoshie,et al.  Inhibition of intravascular mouse melanoma dissemination by recombinant human interferon alpha A/D. , 1986, Japanese journal of cancer research : Gann.

[43]  G Poste,et al.  Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.